{"gene":"TM4SF20","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2014,"finding":"TM4SF20 normally inhibits regulated intramembrane proteolysis (RIP) of the membrane-bound transcription factor CREB3L1. TGF-β stimulates collagen synthesis by inhibiting TM4SF20 expression, thereby relieving this block and allowing CREB3L1 cleavage and nuclear translocation.","method":"Loss-of-function and expression studies in human A549 cells; TGF-β treatment with measurement of TM4SF20 expression, CREB3L1 cleavage, and downstream collagen gene transcription","journal":"PLoS One","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean cellular KD/expression manipulation with defined pathway readout (CREB3L1 cleavage, collagen gene activation), single lab, two orthogonal methods","pmids":["25310401"],"is_preprint":false},{"year":2013,"finding":"A truncating deletion in TM4SF20 that removes exon 3 introduces a premature stop codon, generating a stable but mislocalized protein that accumulates in the cytoplasm rather than targeting to the plasma membrane, consistent with a toxic gain-of-function mechanism.","method":"Minigene analysis, subcellular localization studies of truncated vs. wild-type TM4SF20","journal":"American Journal of Human Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence (cytoplasmic accumulation vs. plasma membrane targeting), single lab, two complementary methods","pmids":["23810381"],"is_preprint":false},{"year":2016,"finding":"Ceramide inverts the membrane topology of TM4SF20 by altering the direction of translocation of its first transmembrane helix during translation (regulated alternative translocation, RAT). In the absence of ceramide, the N terminus of the first TM helix is translocated into the ER lumen (requiring TRAM2); in the presence of ceramide, this translocation is blocked and the N terminus faces the cytosol. The inverted form of TM4SF20 converts it from an inhibitor to an activator of CREB3L1 RIP.","method":"Topology mapping experiments, TRAM2 knockdown, ceramide treatment, in-cell topology assays, functional readout of CREB3L1 cleavage","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (topology mapping, genetic manipulation of TRAM2, ceramide treatment, functional cleavage assay) in a single rigorous study","pmids":["27499293"],"is_preprint":false},{"year":2019,"finding":"Residues in the first transmembrane helix of TM4SF20 are critical for RAT: Asn-26 in the GXXXN motif is essential and cannot be replaced even by Gln; Gly-22 can be substituted by small residues (Ala, Ser) without abolishing RAT; Pro-29 together with Leu-25 or Val-17 are additional required elements. The GXXXN motif alone is insufficient for RAT, as TM4SF4 (which also contains this motif) does not undergo RAT.","method":"Site-directed mutagenesis of TM4SF20, TM4SF20–TM4SF4 chimera analysis, topology assays","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution-level mutagenesis and chimera analysis with functional topology readout, single lab but multiple orthogonal approaches","pmids":["30808712"],"is_preprint":false},{"year":2023,"finding":"TM4SF20 is synthesized in the ER with a cytosolic C terminus and a luminal loop before the last TM helix, where N132, N148, and N163 are glycosylated. In the absence of ceramide, the sequence surrounding glycosylated N163 is retrotranslocated from the ER lumen to the cytosol independently of ER-associated degradation, relocating the C terminus from cytosol to lumen. Ceramide delays this retrotranslocation, causing accumulation of the originally synthesized topology form.","method":"Glycosylation site mapping, fractionation, topology assays with and without ceramide treatment, mutagenesis of glycosylation sites","journal":"Cell Reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (glycosylation mapping, topology assays, ceramide treatment, mutagenesis) in a single study, single lab","pmids":["36972171"],"is_preprint":false},{"year":2021,"finding":"Ceramide-induced RAT of TM4SF20 is crucial for the effectiveness of doxorubicin-based chemotherapy, establishing a physiological importance for the topological inversion mechanism.","method":"Functional cellular assay linking TM4SF20 RAT to doxorubicin chemotherapy response (reviewed/reported in this context)","journal":"Advances in Experimental Medicine and Biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single mention in a review/book chapter without detailed experimental methods described in the abstract","pmids":["32986129"],"is_preprint":false}],"current_model":"TM4SF20 is a polytopic ER/membrane protein that in its default topology inhibits regulated intramembrane proteolysis (RIP) of the transcription factor CREB3L1; ceramide triggers regulated alternative translocation (RAT), inverting the membrane topology of TM4SF20 (a process requiring TRAM2 in the absence of ceramide and key residues Asn-26, Pro-29, Leu-25, and Val-17 in its first TM helix), which converts TM4SF20 into an activator of CREB3L1 cleavage, ultimately promoting collagen synthesis and influencing chemotherapy sensitivity; additionally, the topology of TM4SF20 is further regulated by ceramide-sensitive retrotranslocation of its glycosylated luminal loop back to the cytosol."},"narrative":{"mechanistic_narrative":"TM4SF20 is a polytopic endoplasmic reticulum membrane protein that controls the regulated intramembrane proteolysis (RIP) of the membrane-bound transcription factor CREB3L1, thereby gating collagen synthesis [PMID:25310401]. In its default state TM4SF20 blocks CREB3L1 cleavage; TGF-β relieves this block by suppressing TM4SF20 expression, permitting CREB3L1 cleavage, nuclear translocation, and activation of collagen genes [PMID:25310401]. The protein's activity is dictated by its membrane topology, which ceramide reverses through regulated alternative translocation (RAT): in the absence of ceramide the N terminus of the first transmembrane helix is translocated into the ER lumen in a TRAM2-dependent manner, whereas ceramide blocks this translocation so the N terminus faces the cytosol, converting TM4SF20 from an inhibitor into an activator of CREB3L1 RIP [PMID:27499293]. RAT depends on specific determinants in the first TM helix—the GXXXN motif residue Asn-26 is essential, with Pro-29 acting together with Leu-25 or Val-17, while the GXXXN motif alone is insufficient [PMID:30808712]. Topology is further tuned by ceramide-sensitive retrotranslocation of a glycosylated luminal loop (N132, N148, N163) back to the cytosol independently of ER-associated degradation, which repositions the C terminus and is delayed by ceramide [PMID:36972171]. A truncating deletion removing exon 3 produces a stable protein that mislocalizes to the cytoplasm rather than the plasma membrane, consistent with a toxic gain-of-function mechanism [PMID:23810381].","teleology":[{"year":2013,"claim":"Establishing that TM4SF20 mislocalization has pathological consequences, a truncating variant was shown to generate a stable protein that accumulates in the cytoplasm rather than reaching its normal membrane destination.","evidence":"Minigene analysis and subcellular localization of truncated vs. wild-type protein","pmids":["23810381"],"confidence":"Medium","gaps":["Does not define the normal molecular function of TM4SF20","Toxic gain-of-function mechanism inferred from localization, not directly demonstrated","No link to the CREB3L1/ceramide pathway established at this point"]},{"year":2014,"claim":"Defining TM4SF20's first known function, it was shown to inhibit RIP of CREB3L1 and to act as the node through which TGF-β relieves this block to drive collagen synthesis.","evidence":"Loss-of-function and expression studies in A549 cells with CREB3L1 cleavage and collagen gene readouts","pmids":["25310401"],"confidence":"Medium","gaps":["Mechanism by which TM4SF20 blocks CREB3L1 cleavage not resolved","Single cell line, single lab","Direct physical interaction with CREB3L1 not demonstrated"]},{"year":2016,"claim":"Explaining how TM4SF20 switches between inhibitor and activator states, ceramide was shown to invert its membrane topology via regulated alternative translocation, with TRAM2 required for luminal translocation in the absence of ceramide.","evidence":"Topology mapping, TRAM2 knockdown, ceramide treatment, and functional CREB3L1 cleavage assays","pmids":["27499293"],"confidence":"High","gaps":["How the inverted topology mechanistically activates CREB3L1 RIP not detailed","Source/sensing of ceramide upstream not defined","Structural basis of the topology switch not resolved"]},{"year":2019,"claim":"Defining the sequence determinants of the topology switch, mutagenesis identified Asn-26 of the GXXXN motif as essential and Pro-29 with Leu-25 or Val-17 as required, while showing the GXXXN motif alone is insufficient.","evidence":"Site-directed mutagenesis, TM4SF20–TM4SF4 chimera analysis, and topology assays","pmids":["30808712"],"confidence":"High","gaps":["How these residues mechanistically govern translocation direction unknown","No structural model of the first TM helix during RAT","Additional non-helix determinants not excluded"]},{"year":2023,"claim":"Revealing a second layer of topological control, the luminal loop was mapped to glycosylated N132/N148/N163 and shown to retrotranslocate to the cytosol independently of ERAD, a step ceramide delays to stabilize the originally synthesized form.","evidence":"Glycosylation site mapping, fractionation, topology assays, and glycosylation-site mutagenesis with/without ceramide","pmids":["36972171"],"confidence":"High","gaps":["Machinery driving the ERAD-independent retrotranslocation unidentified","Functional consequence of C-terminal repositioning for CREB3L1 control not fully linked","How ceramide delays retrotranslocation mechanistically unknown"]},{"year":2021,"claim":"Linking the topology mechanism to physiology, ceramide-induced RAT of TM4SF20 was reported as important for doxorubicin chemotherapy effectiveness.","evidence":"Functional cellular assay reported in a review/book chapter","pmids":["32986129"],"confidence":"Low","gaps":["Reported in a review without detailed experimental methods in the abstract","Mechanistic link between RAT and drug response not delineated","Not independently confirmed in the timeline"]},{"year":null,"claim":"How the topology-determined inhibitor/activator states physically engage the CREB3L1 RIP machinery, and the identity of the retrotranslocation apparatus, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No defined direct interaction between TM4SF20 and CREB3L1 or its proteases","ERAD-independent retrotranslocation machinery unidentified","Upstream ceramide-generating signals controlling RAT undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,4]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,4]}],"complexes":[],"partners":["CREB3L1","TRAM2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q53R12","full_name":"Transmembrane 4 L6 family member 20","aliases":[],"length_aa":229,"mass_kda":25.1,"function":"Polytopic transmembrane protein that inhibits regulated intramembrane proteolysis (RIP) of CREB3L1, inhibiting its activation and the induction of collagen synthesis (PubMed:25310401, PubMed:27499293). In response to ceramide, which alters TM4SF20 membrane topology, stimulates RIP activation of CREB3L1 (PubMed:27499293). Ceramide reverses the direction through which transmembrane helices are translocated into the endoplasmic reticulum membrane during translation of TM4SF20, this mechanism is called 'regulated alternative translocation' (RAT) and regulates the function of the transmembrane protein (PubMed:27499293)","subcellular_location":"Membrane; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q53R12/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TM4SF20","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TM4SF20","total_profiled":1310},"omim":[{"mim_id":"619773","title":"IMMUNODEFICIENCY 95; IMD95","url":"https://www.omim.org/entry/619773"},{"mim_id":"615432","title":"SPECIFIC LANGUAGE IMPAIRMENT 5; SLI5","url":"https://www.omim.org/entry/615432"},{"mim_id":"615404","title":"TRANSMEMBRANE 4 L6 FAMILY, MEMBER 20; TM4SF20","url":"https://www.omim.org/entry/615404"},{"mim_id":"606951","title":"INTERFERON-INDUCED HELICASE C DOMAIN-CONTAINING PROTEIN 1; IFIH1","url":"https://www.omim.org/entry/606951"},{"mim_id":"606711","title":"SPECIFIC LANGUAGE IMPAIRMENT 1; SLI1","url":"https://www.omim.org/entry/606711"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Focal adhesion sites","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":251.2}],"url":"https://www.proteinatlas.org/search/TM4SF20"},"hgnc":{"alias_symbol":["FLJ22800","TCCE518"],"prev_symbol":[]},"alphafold":{"accession":"Q53R12","domains":[{"cath_id":"1.20.120","chopping":"2-37_48-114_182-222","consensus_level":"medium","plddt":86.0458,"start":2,"end":222}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q53R12","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q53R12-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q53R12-F1-predicted_aligned_error_v6.png","plddt_mean":73.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TM4SF20","jax_strain_url":"https://www.jax.org/strain/search?query=TM4SF20"},"sequence":{"accession":"Q53R12","fasta_url":"https://rest.uniprot.org/uniprotkb/Q53R12.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q53R12/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q53R12"}},"corpus_meta":[{"pmid":"25310401","id":"PMC_25310401","title":"Sustained induction of collagen synthesis by TGF-β requires regulated intramembrane proteolysis of CREB3L1.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25310401","citation_count":52,"is_preprint":false},{"pmid":"23810381","id":"PMC_23810381","title":"TM4SF20 ancestral deletion and susceptibility to a pediatric disorder of early language delay and cerebral white matter hyperintensities.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23810381","citation_count":42,"is_preprint":false},{"pmid":"27499293","id":"PMC_27499293","title":"Inverting the Topology of a Transmembrane Protein by Regulating the Translocation of the First Transmembrane Helix.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27499293","citation_count":37,"is_preprint":false},{"pmid":"32487748","id":"PMC_32487748","title":"Transcription factors activated through RIP (regulated intramembrane proteolysis) and RAT (regulated alternative translocation).","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32487748","citation_count":27,"is_preprint":false},{"pmid":"34540591","id":"PMC_34540591","title":"Study of rare genetic variants in TM4SF20, NFXL1, CNTNAP2, and ATP2C2 in Pakistani probands and families with language impairment.","date":"2021","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/34540591","citation_count":8,"is_preprint":false},{"pmid":"30808712","id":"PMC_30808712","title":"Identification of residues critical for topology inversion of the transmembrane protein TM4SF20 through regulated alternative translocation.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30808712","citation_count":5,"is_preprint":false},{"pmid":"36972171","id":"PMC_36972171","title":"Topological regulation of a transmembrane protein by luminal-to-cytosolic retrotranslocation of glycosylated sequence.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36972171","citation_count":4,"is_preprint":false},{"pmid":"32986129","id":"PMC_32986129","title":"Regulated Alternative Translocation: A Mechanism Regulating Transmembrane Proteins Through Topological Inversion.","date":"2021","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32986129","citation_count":1,"is_preprint":false},{"pmid":"36711494","id":"PMC_36711494","title":"Global Transcriptomics of Congenital Hepatic Fibrosis in Autosomal Recessive Polycystic Kidney Disease using PCK rats.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/36711494","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6437,"output_tokens":1703,"usd":0.022428,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8517,"output_tokens":2589,"usd":0.053655,"stage2_stop_reason":"end_turn"},"total_usd":0.076083,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"TM4SF20 normally inhibits regulated intramembrane proteolysis (RIP) of the membrane-bound transcription factor CREB3L1. TGF-β stimulates collagen synthesis by inhibiting TM4SF20 expression, thereby relieving this block and allowing CREB3L1 cleavage and nuclear translocation.\",\n      \"method\": \"Loss-of-function and expression studies in human A549 cells; TGF-β treatment with measurement of TM4SF20 expression, CREB3L1 cleavage, and downstream collagen gene transcription\",\n      \"journal\": \"PLoS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean cellular KD/expression manipulation with defined pathway readout (CREB3L1 cleavage, collagen gene activation), single lab, two orthogonal methods\",\n      \"pmids\": [\"25310401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A truncating deletion in TM4SF20 that removes exon 3 introduces a premature stop codon, generating a stable but mislocalized protein that accumulates in the cytoplasm rather than targeting to the plasma membrane, consistent with a toxic gain-of-function mechanism.\",\n      \"method\": \"Minigene analysis, subcellular localization studies of truncated vs. wild-type TM4SF20\",\n      \"journal\": \"American Journal of Human Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence (cytoplasmic accumulation vs. plasma membrane targeting), single lab, two complementary methods\",\n      \"pmids\": [\"23810381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Ceramide inverts the membrane topology of TM4SF20 by altering the direction of translocation of its first transmembrane helix during translation (regulated alternative translocation, RAT). In the absence of ceramide, the N terminus of the first TM helix is translocated into the ER lumen (requiring TRAM2); in the presence of ceramide, this translocation is blocked and the N terminus faces the cytosol. The inverted form of TM4SF20 converts it from an inhibitor to an activator of CREB3L1 RIP.\",\n      \"method\": \"Topology mapping experiments, TRAM2 knockdown, ceramide treatment, in-cell topology assays, functional readout of CREB3L1 cleavage\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (topology mapping, genetic manipulation of TRAM2, ceramide treatment, functional cleavage assay) in a single rigorous study\",\n      \"pmids\": [\"27499293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Residues in the first transmembrane helix of TM4SF20 are critical for RAT: Asn-26 in the GXXXN motif is essential and cannot be replaced even by Gln; Gly-22 can be substituted by small residues (Ala, Ser) without abolishing RAT; Pro-29 together with Leu-25 or Val-17 are additional required elements. The GXXXN motif alone is insufficient for RAT, as TM4SF4 (which also contains this motif) does not undergo RAT.\",\n      \"method\": \"Site-directed mutagenesis of TM4SF20, TM4SF20–TM4SF4 chimera analysis, topology assays\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution-level mutagenesis and chimera analysis with functional topology readout, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"30808712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TM4SF20 is synthesized in the ER with a cytosolic C terminus and a luminal loop before the last TM helix, where N132, N148, and N163 are glycosylated. In the absence of ceramide, the sequence surrounding glycosylated N163 is retrotranslocated from the ER lumen to the cytosol independently of ER-associated degradation, relocating the C terminus from cytosol to lumen. Ceramide delays this retrotranslocation, causing accumulation of the originally synthesized topology form.\",\n      \"method\": \"Glycosylation site mapping, fractionation, topology assays with and without ceramide treatment, mutagenesis of glycosylation sites\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (glycosylation mapping, topology assays, ceramide treatment, mutagenesis) in a single study, single lab\",\n      \"pmids\": [\"36972171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ceramide-induced RAT of TM4SF20 is crucial for the effectiveness of doxorubicin-based chemotherapy, establishing a physiological importance for the topological inversion mechanism.\",\n      \"method\": \"Functional cellular assay linking TM4SF20 RAT to doxorubicin chemotherapy response (reviewed/reported in this context)\",\n      \"journal\": \"Advances in Experimental Medicine and Biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single mention in a review/book chapter without detailed experimental methods described in the abstract\",\n      \"pmids\": [\"32986129\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TM4SF20 is a polytopic ER/membrane protein that in its default topology inhibits regulated intramembrane proteolysis (RIP) of the transcription factor CREB3L1; ceramide triggers regulated alternative translocation (RAT), inverting the membrane topology of TM4SF20 (a process requiring TRAM2 in the absence of ceramide and key residues Asn-26, Pro-29, Leu-25, and Val-17 in its first TM helix), which converts TM4SF20 into an activator of CREB3L1 cleavage, ultimately promoting collagen synthesis and influencing chemotherapy sensitivity; additionally, the topology of TM4SF20 is further regulated by ceramide-sensitive retrotranslocation of its glycosylated luminal loop back to the cytosol.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TM4SF20 is a polytopic endoplasmic reticulum membrane protein that controls the regulated intramembrane proteolysis (RIP) of the membrane-bound transcription factor CREB3L1, thereby gating collagen synthesis [#0]. In its default state TM4SF20 blocks CREB3L1 cleavage; TGF-\\u03b2 relieves this block by suppressing TM4SF20 expression, permitting CREB3L1 cleavage, nuclear translocation, and activation of collagen genes [#0]. The protein's activity is dictated by its membrane topology, which ceramide reverses through regulated alternative translocation (RAT): in the absence of ceramide the N terminus of the first transmembrane helix is translocated into the ER lumen in a TRAM2-dependent manner, whereas ceramide blocks this translocation so the N terminus faces the cytosol, converting TM4SF20 from an inhibitor into an activator of CREB3L1 RIP [#2]. RAT depends on specific determinants in the first TM helix\\u2014the GXXXN motif residue Asn-26 is essential, with Pro-29 acting together with Leu-25 or Val-17, while the GXXXN motif alone is insufficient [#3]. Topology is further tuned by ceramide-sensitive retrotranslocation of a glycosylated luminal loop (N132, N148, N163) back to the cytosol independently of ER-associated degradation, which repositions the C terminus and is delayed by ceramide [#4]. A truncating deletion removing exon 3 produces a stable protein that mislocalizes to the cytoplasm rather than the plasma membrane, consistent with a toxic gain-of-function mechanism [#1].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Establishing that TM4SF20 mislocalization has pathological consequences, a truncating variant was shown to generate a stable protein that accumulates in the cytoplasm rather than reaching its normal membrane destination.\",\n      \"evidence\": \"Minigene analysis and subcellular localization of truncated vs. wild-type protein\",\n      \"pmids\": [\"23810381\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Does not define the normal molecular function of TM4SF20\",\n        \"Toxic gain-of-function mechanism inferred from localization, not directly demonstrated\",\n        \"No link to the CREB3L1/ceramide pathway established at this point\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defining TM4SF20's first known function, it was shown to inhibit RIP of CREB3L1 and to act as the node through which TGF-\\u03b2 relieves this block to drive collagen synthesis.\",\n      \"evidence\": \"Loss-of-function and expression studies in A549 cells with CREB3L1 cleavage and collagen gene readouts\",\n      \"pmids\": [\"25310401\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which TM4SF20 blocks CREB3L1 cleavage not resolved\",\n        \"Single cell line, single lab\",\n        \"Direct physical interaction with CREB3L1 not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Explaining how TM4SF20 switches between inhibitor and activator states, ceramide was shown to invert its membrane topology via regulated alternative translocation, with TRAM2 required for luminal translocation in the absence of ceramide.\",\n      \"evidence\": \"Topology mapping, TRAM2 knockdown, ceramide treatment, and functional CREB3L1 cleavage assays\",\n      \"pmids\": [\"27499293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How the inverted topology mechanistically activates CREB3L1 RIP not detailed\",\n        \"Source/sensing of ceramide upstream not defined\",\n        \"Structural basis of the topology switch not resolved\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defining the sequence determinants of the topology switch, mutagenesis identified Asn-26 of the GXXXN motif as essential and Pro-29 with Leu-25 or Val-17 as required, while showing the GXXXN motif alone is insufficient.\",\n      \"evidence\": \"Site-directed mutagenesis, TM4SF20\\u2013TM4SF4 chimera analysis, and topology assays\",\n      \"pmids\": [\"30808712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How these residues mechanistically govern translocation direction unknown\",\n        \"No structural model of the first TM helix during RAT\",\n        \"Additional non-helix determinants not excluded\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealing a second layer of topological control, the luminal loop was mapped to glycosylated N132/N148/N163 and shown to retrotranslocate to the cytosol independently of ERAD, a step ceramide delays to stabilize the originally synthesized form.\",\n      \"evidence\": \"Glycosylation site mapping, fractionation, topology assays, and glycosylation-site mutagenesis with/without ceramide\",\n      \"pmids\": [\"36972171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Machinery driving the ERAD-independent retrotranslocation unidentified\",\n        \"Functional consequence of C-terminal repositioning for CREB3L1 control not fully linked\",\n        \"How ceramide delays retrotranslocation mechanistically unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linking the topology mechanism to physiology, ceramide-induced RAT of TM4SF20 was reported as important for doxorubicin chemotherapy effectiveness.\",\n      \"evidence\": \"Functional cellular assay reported in a review/book chapter\",\n      \"pmids\": [\"32986129\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Reported in a review without detailed experimental methods in the abstract\",\n        \"Mechanistic link between RAT and drug response not delineated\",\n        \"Not independently confirmed in the timeline\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the topology-determined inhibitor/activator states physically engage the CREB3L1 RIP machinery, and the identity of the retrotranslocation apparatus, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No defined direct interaction between TM4SF20 and CREB3L1 or its proteases\",\n        \"ERAD-independent retrotranslocation machinery unidentified\",\n        \"Upstream ceramide-generating signals controlling RAT undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CREB3L1\", \"TRAM2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}